🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Plasma Biomarker in Amblyopia Patients

Recruitingn/aAges 3 Years - 12 YearsAllZhongshan Ophthalmic Center, Sun Yat-sen Universi…
NCT05705778 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosed with amblyopia * 3-12 years of age * Able to tolerate amblyopia treatment * Agree to be involved in this study and agree to have a follow up visit every 3 months. Exclusion Criteria: * Have previous treatment history before * Have pathological ocular anomalies known to cause reduced visual acuity * Have previous psychiatric, visual or neurological disorders * Have eccentric fixation and/or abnormal retinal correspondence * Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves
💊

What it tests

  • standard amblyopia treatment
📍

Where

1 site
Zhongshan Ophthalmic Center
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy